Issue link: https://beckershealthcare.uberflip.com/i/1494056
23 DEVICES & IMPLANTS Johnson & Johnson's orthopedics sales dip in Q4: 5 notes By Carly Behm J ohnson & Johnson on Jan. 24 posted $23.7 billion in 2022 revenue, a 4.4 percent decrease. Its orthopedic sales remained flat year-over-year, and its fourth- quarter orthopedic sales fell slightly. Five things to know: 1. Orthopedic sales in the fourth quarter was $2.1 billion, a 0.4 percent decrease. Hip sales rose 1.7 percent year-over-year in the fourth quarter with $385 million, and knee sales grew 3.4 percent with $354 million. 2. Fourth quarter trauma sales fell 2.4 percent year-over- year with $710 million. The spine and sports medicine segments saw $699 million in fourth qarter sales, a 1.3 percent year-over-year decrease. 3. Full-year orthopedic sales of $8.6 billion was the same compared to 2021 sales. 4. MedTech business as a whole brought in $6.8 billion on 2022, a 1.2 percent decrease from 2021. 5. Johnson & Johnson expects 2023 operational revenue to grow 3.5 percent. n Zimmer Biomet to acquire orthobiologics company for $155M By Carly Behm Zimmer Biomet signed an agreement to acquire Embody, an orthobiologics company, for $155 million. The acquisition is expected to close in February, Zimmer Biomet said in a Jan. 5 news release. Along with the upfront cost, Zimmer Biomet could pay an additional $120 million subject to meeting regulatory and commercial milestones over three years. Embody focuses on soft tissue healing, and its portfolio includes the Tapestry biointegrative implant for tendon healing and Tapestry RC implant for rotator cuff repair. "Embody's differentiated products and innovative pipeline in the area of sports medicine support our continued focus on and investment in high-growth markets and underscores our commitment to bringing meaningful new advances to patients and surgeons," Bryan Hanson, president and CEO of Zimmer Biomet said in the release. n Stryker expects Mako spine application to launch in 2024 By Carly Behm S tryker's spine and shoulder applications for the Mako robot are expected to launch in 2024, according to a Jan. 31 earnings call. The company's vice president of investor relations, Jason Beach, said there is "good progress" on Mako spine and shoulder's development, as transcribed by Seeking Alpha. Mako spine is expected to launch in the second half of 2024, and the initial shoulder launch is slated toward the end of 2024. In Stryker's previous earnings call in November, CEO Kevin Lobo did not have an exact prediction on when to expect Mako spine and shoulder. Now, he said prototypes have been built and tested with surgeons, giving the company confidence in the expected 2024 launch. "The beauty of our approach is it's the same robot that's being used for hips and knees that's going to be used, and we have thousands of them now out there," he said. "[It is] exciting that we will be able to just do a software upgrade, have a different attachment and be able to use the same robot. I think a lot of hospitals will be excited about that." n Orthopedic devicemaker behind BEAR implant snags $40M financing By Carly Behm M iach Orthopaedics secured $40 million in financing to help expand commercialization of the Bridge-Enhanced ACL Restoration, the devicemaker said Jan. 25. The financing includes $30 million in Series B equity and a $10 million venture debt term sheet, according to a news relese. The BEAR implant was launched in 2021 and have been used with more than 500 patients, Patrick McBrayer, president and CEO of Miach Orthopaedics, said in the release. The most recent city to add the implant is Buffalo, N.Y. where Peter Gambacorta, DO, completed the debut case. The BEAR implant uses a patient's own blood to bridge and repair their ACL. n